Maintaining ERBB Blockade in EGFR-mutated Lung Cancer
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This study aims to compare the efficacy of afatinib maintenance with pemetrexed maintenance
following induction therapy with platinum/ pemetrexed in patients with metastatic epidermal
growth factor receptor (EGFR) mutated non-small-cell lung cancer (NSCLC) progressing after
first-line treatment with afatinib with respect to progression-free survival.